Discussions

Introduction

Protheragen has expanded its 13C/14C-labeled compound portfolio to support research in metabolic pathways, pharmacokinetics, breath assays, and biochemical tracing. The expanded lineup improves options for high-accuracy molecular tracing and supports consistent data output in metabolism and drug distribution research. Researchers can now explore a broad selection of 13C- and 14C-labeled products designed to meet a wide range of experimental needs.

Due to the rising global obesity rates and the rapidly growing clinical demand for treatments, pharmaceutical companies are increasingly turning to GLP-1 receptor agonists, which play an important role in both the treatment of type 2 diabetics and weight-management therapies. But according to the U.S. Food and Drug Administration’s (FDA) public drug shortages database, the supplies are now remaining constrained.

Despite the high degree of disability from late neurological deficits, and as a leading cause of both long-term memory impairments and death worldwide, effective restorative strategies for brain parenchyma damaged by IR injury have been stalled due to deficiencies in existing animal models. Ace Therapeutics in vitro stroke models find a solution to both of these challenges, through the use of human-relevant and precise reversible experimental conditions. The service has dedicated models for both of the two main stroke types:

Ace Therapeutics, a preclinical contract research provider, announced recently that it has launched in vivo efficacy testing services for IBD drug candidates. Building on in vitro successes to translate into clinical advances, the services meld state-of-the-art precision with affordable solutions that enable biotech and pharmaceutical organizations to expedite their IBD drug discovery efforts.